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Effect of Her2 Expression on Nupl2 Protein  
in Cervical Cancer Cells 
 
Mary E. Eichholz, Margaret J. Ballou, Tristan J. Haight,  
Jennifer L. Minton, Ryan N. Oates, & Jacob J. Adler 
Brescia University 
 
Abstract: Recurring cervical cancer patients frequently present overexpressed Human Epidermal 
Growth Factor Receptor 2 (HER2) protein, which promotes the growth of the cancer. Some HER2-
expressing cells and cervical cancer patients have enhanced gene expression of Nucleoporin-like 2 
(NUPL2). As part of the nuclear pore complex, the NUPL2 protein serves to selectively export 
substances from the nucleus to the cytoplasm. In this experiment, HER2 was expressed in cervical 
cancer cells to examine its effect on NUPL2 protein expression and localization. Interestingly, there 
was no difference in NUPL2 protein levels between HER2-expressing and non-expressing cells. 
Importantly, consistent instances of NUPL2 protein localization specific to the nucleus occurred in 
a large sampling of HER2-expressing cells. This is significant because it suggests a mechanism as 
to how HER2 promotes excessive cell growth, via changes in NUPL2 localization, potentially 
impacting its function and ability to selectively export substances that modulate cell growth. 
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Cervical cancer is the fourth leading cause of cancer deaths 
in women worldwide (Bray et al., 2018). Frequently, patients 
with recurring cervical cancer have highly expressed Human 
Epidermal Growth Factor Receptor 2 (HER2) protein (Chavez-
Blanco et al., 2004), a documented powerful cancer driver 
(Moasser, 2007). Many types of cancers are promoted by 
deregulating cellular nucleoporins, which are proteins of the 
nuclear pore complex involved in the transportation of gene 
transcripts, regulation of transcription, and chromatin access 
(Köhler & Hurt, 2010; Kau et al., 2004). Importantly, one of 
these nucleoporins, Nucleoporin-like 2 (NUPL2), shows 
enhanced gene expression in HER2-positive breast cancer cell 
lines and tissues (Kalari et al., 2013; Wilson et al., 2002). No 
published data sets exist comparing HER2-positive cervical 
cancers and NUPL2 gene expression; however, cervical cancer 
patient samples do present significantly higher NUPL2 gene 
expression compared to control samples via microarray analysis 
(Long et al., 2017). Additionally, the RNA transport pathway (of 
which NUPL2 protein is a member) was found to be a key 
mechanism involved in the initiation, progression, and 
metastasis of cervical cancer (Long et al., 2017).  
Interestingly, the NUPL2 gene is amplified in 1% of cervical 
cancer patients and shows higher gene expression levels 
compared to controls according to cBioPortal for Cancer 
Genomics (Cerami et al., 2012; Gao et al., 2013). However, 
cervical squamous cell carcinoma patients show no significant 
difference in NUPL2 gene expression between cancer grades, 
stages, nor survival according to UALCAN web-portal 
(Chandrasekhar et al., 2017). Together, these large data set 
studies have suggested a possible link between HER2 expression 
and NUPL2 protein in cervical cancer, but this connection has 
not been reported. Based upon the data independently 
demonstrating cervical cancer and HER2-expression changes to 
gene expression of NUPL2, and the importance of NUPL2 
localization for its function, here we examined the protein levels 
of NUPL2 with immunoblot and its localization via 
immunofluorescence in response to HER2 overexpression in 
HeLa cells. In the current study, we sought to examine whether 
the expression of HER2 could modify the protein expression, or 
the location of NUPL2 protein, or both, and as a result, could 





Cell Culture  
HeLa cells were grown in DMEM with Glutamax (Gibco 
10565018) supplemented with Fetal Bovine Serum (10%) (FBS) 
(Atlanta Biologicals) and Antibiotic-Antimycotic (Gibco 
15240062). For immunoblot experiments, cells were plated at 
70,000 cells/well on a 6 cm plate. For immunofluorescence 
experiments, cells were plated at 10,000 cells/well on an 8-well 
chamber slide. For both experiments, cells were grown for 24 
hours. Plasmid DNA, either control pcDNA3.1-EGFP or 
pERBB2-EGFP (Addgene plasmid # 39321), was transfected 
with Lipofectamine 3000 (ThermoFisher Scientific L3000001) 
via manufacture instructions. Cells were allowed to grow for 24 
hours then used for assays.  
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HeLa cells on 6 cm plates were washed twice with 
phosphate buffered saline (PBS) on ice and scraped into a 
microcentrifuge tube. Cells were microcentrifuged at 4 °C at 600 
X g for 2 minutes and then the supernatant was discarded. The 
cell pellets were resuspended with a RIPA lysis buffer (50 mM 
Tris-HCl pH 7.4, 1% NP-40, 0.5% Sodium-deoxycholate, 0.1% 
SDS, 150 mM NaCl, 2 mM EDTA pH 8.0, 50 mM NaF) 
supplemented with a protease inhibitor cocktail (Sigma S8820-
2TAB) then passed 50 times with a P200 micropipette. Samples 
were placed on dry ice for 2 minutes, then removed from dry ice 
and warmed quickly. Samples were passed 50 times again with 
a P200 micropipette and placed back on dry ice for 2 minutes. 
Samples were warmed quickly and then placed on ice for 10 
minutes. Samples were microcentrifuged at 4 °C for 10 minutes 
at 20,000 X g. The supernatant was removed and used with 
common SDS-PAGE and liquid transfer of proteins on 
nitrocellulose protocols. Anti-GFP antibody (Sigma G6539) was 
used at a 1:1000 dilution in PBS-Tween. Anti-NUPL2 antibody 
(Abcam EPR16545) was used at a 1:1000 dilution in PBS-
Tween. Anti-GAPDH antibody (Cell Signaling 5174T) was used 
at a 1:1000 dilution in PBS-Tween. All antibodies were 
incubated with nitrocellulose blots overnight on a rocking 
platform at 4 °C. Anti-Rabbit and anti-Mouse IgG HRP-linked 
antibodies (Cell Signaling 7074 and 7076) were used at 1:1000 
dilutions and incubated at room temperature for 30 minutes on a 
rocking platform. HRP Conjugate Substrate Kit (BioRad 
1706431) was used to detect HRP secondary antibodies via 
manufacturer directions. Images were acquired using the gel 
imaging system (BioRad Gel Doc 2000 Chemi Doc 1708126). 
 
Immunofluorescence 
HeLa cells on chamber slides were fixed with a 4% 
paraformaldehyde solution in PBS for 10 minutes at room 
temperature. Cells were then permeabilized with a 0.5% Tween-
20 in PBS solution for 10 minutes at room temperature. Finally, 
cells were blocked in a 3% Goat Serum (Sigma G9023) in PBS 
overnight at 4 °C. Prior to each step above, cells were washed 3 
times for 3 minutes each with PBS. Fixed cells were then 
incubated with the primary antibody NUPL2 (Abcam 
EPR16545) diluted 1:100 in 3% Goat Serum for 1 hour at 4 °C.  
Secondary antibody Goat anti-Rabbit Alexa Fluor 594 
(ThermoFisher R37177) was diluted 1:500 in 3% Goat Serum 
and incubated for 30 minutes at 4 °C in dark. DAPI Stain 
(Chemical FL 341 Blue) (Pierce 62248) was diluted to a final 
concentration 1 μg/mL and applied to each well for 8 minutes at 
room temperature in dark. Between each step above, wells were 
washed 3 times with PBS. Chamber slides were dismantled and 
washed twice gently with ultrapure water. Slides were dried and 
mounted with coverslips with ProLong Glass Antifade Mountant 
(Invitrogen P36982) per manufacturer directions. Slides were 
imaged using the EVOS FL imaging system (Life Technologies). 
EVOS LED GFP light cube (AMEP4651) was used to analyze 
GFP-expressing HeLa cells. EVOS LED TexasRed light cube 
(AMEP4655) was used to analyze NUPL2/Alexa Fluor 594.  
EVOS LED DAPI light cube (AMEP4650) was used to analyze 
DAPI Stain. Analysis of immunofluorescence data was 
completed using ImageJ (https://imagej.nih.gov/ij/download/). 
 
Results 
Since several studies indicate changes to NUPL2 gene 
expression in HER2-positive breast samples (Kalari et al., 2013; 
Wilson et al., 2002), and in cervical cancer patients (Long et al., 
2017), the protein levels of NUPL2 were examined via 
immunoblot. NUPL2 protein levels remained unchanged 
between HER2-expressing and non-expressing HeLa cells 
(Figure 1). This indicates an inability for high levels of HER2 to 
compromise the normal protein expression or stability of NUPL2 
in these cells.  
Previous work showed that NUPL2 protein localized 
primarily around the nucleoplasm, and some cytoplasmic 
staining in HeLa cells according to The Human Protein Atlas 
(Thul et al., 2017). NUPL2 presents its functionality in the 
nucleus as a part of the nuclear pore complex (Köhler & Hurt, 
2010); thus immunofluorescence was used to examine the 
localization of NUPL2 in HER2-expressing cells (Figure 2). 
Importantly, NUPL2 localized within the nucleus in 65% of cells 
expressing HER2 (N = 100), compared to just 20% access in the 
non-expressing cells (N = 180) (Table 1). Interestingly, only in 
HER2-expressing cells did NUPL2 exclusively localize to the 
nucleus. There was a decreased corresponding 56% change in 
cytosolic localization of NUPL2 in the HER2-expressing cells 
compared to non-expressing cells. Together these data indicate a 










Figure 1. Immunoblot detection of NUPL2 protein in HER2-expressing HeLa cells.  HeLa cells transfected with GFP-tagged vector 
control or with GFP-tagged HER2 were then harvested for protein and used for immunoblot using antibodies specific for NUPL2, GFP, 
and GAPDH. Three independent samples are provided per condition. 
 
 
Figure 2. Immunofluorescence detection of NUPL2 protein in HER2-expressing HeLa cells. HeLa cells transfected without or with 
GFP-tagged HER2 (green) using an antibody for NUPL2 (red). Cells were co-stained for nuclei (blue) in overlay with the other two 
channels (merge). 
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 Nucleus Only Both Cytosol Only 
Control  
(N = 180) 
0 % 20 % 80 % 
HER2  
(N = 100) 





Table 1. NUPL2 localization in HER2-expressing HeLa cells. The quantification of localization of NUPL2 (red) in HeLa cells 
transfected without (Control) (N = 180 cells) or with HER2 (N = 100 cells). Cells were analyzed by three separate investigators in the 
blind. Nucleus Only = residing visibly only in nucleus; Cytosol only = residing visibly only outside the nucleus; Both = residing visibly 





Prior to this investigation, there were no published studies 
examining the impact of HER2 expression on NUPL2 protein in 
any cell line. In fact, in cervical cancer cells, NUPL2 protein 
levels and localization have only been reported previously in 
HeLa cells found on (Abcam EPR16545) and The Human 
Protein Atlas (Thul et al., 2017), and not in cervical cancer cell 
lines expressing high HER2 (SiHa, C33A, CaSki) (Narisawa-
Saito et al., 2006). Future studies on HER2 in cervical cancer 
might examine these cell lines with higher HER2 expression for 
NUPL2 protein to see if there are relative change in basal levels. 
This study is the first to characterize the role of HER2 expression 
on NUPL2 protein with immunoblot and immunofluorescence 
data. The data clearly demonstrates that expression of HER2 
does not influence the protein levels of NUPL2 in HeLa cells. 
This is critical information for the field, as previous studies 
demonstrated a change in the NUPL2 gene expression levels in 
HER2-positive breast tissues via cDNA microarray and RNA-
Seq data sets (Wilson et al., 2002; Kalari et al., 2013) and in 
cervical cancer patient samples (Long et al., 2017). It is likely 
that other unknown tissue- and organ-specific factors such as 
hormones or post-translational processing may be important to 
the regulation of NUPL2 protein production, of which HER2 
may be a corresponding factor.  
The immunofluorescence data paints an intriguing role of 
HER2 expression in the localization of NUPL2 protein.  Studies 
have shown that when NUPL2 protein and other nucleoporins 
are deregulated, these proteins function to promote cell growth 
and cancer proliferation (Nofrini et al., 2016). The localization 
change of NUPL2 to the nucleus suggests that HER2 expression 
could impact the functionality of NUPL2 in HeLa cells. 
Interactome enrichment studies have shown that other 
nucleoporins could be deregulated in HER2-positive tumors 
(Kalari et al., 2013; Long et al., 2017). In conclusion, these 
findings provide initial information about the relationship 
between NUPL2 protein and HER2 expression in cells. This data 
provides the foundational knowledge to explore NUPL2 and 
other nucleoporins and isolate their relationships in HER2-
positive recurring cervical cancer patients. Perhaps NUPL2 
could indicate a viable mechanistic target for understanding and 
unlocking new nucleoporin-related gene therapy options.  
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